Possible alternative measures of amenable mortality, illustrated for four candidate conditions
| HIV/AIDS | HIV/AIDS | Hodgkin's disease | Hodgkin's disease | Breast cancer | Breast cancer | Cerebrovascular disease | Cerebrovascular disease | Cerebrovascular disease | |
| Timing of start of mortality decline, by gender (95% CIs) | % Mortality decline per year since start of mortality decline, by gender (95% CIs) | Timing of start of mortality decline, by gender (95% CIs) | % Decline per year since 1984 (95% CIs) | Timing of start of mortality decline (95% CIs) | % Mortality decline per year since favourable change (95% CIs) | Timing of start of mortality decline due to detection and treatment of hypertension, by gender (95% CIs) | % Decline per year since start of mortality decline due to detection and treatment of hypertension, by gender (95% CIs) | Timing of start of mortality decline due to intensive management, by gender (95% CIs) | |
| UK | M: 1996 (95 to 96) | M: 18.0 (8.9 to 26.1) | NA | M: 4.4 (3.9 to 4.9) | F: 1989 (88 to 89) | F: 2.3 (2.1 to 2.4) | M: 1984 (84 to 84) | 3.5 (3.3 to 3.7) | M: 2003 (03 to 03) |
| F: 1996 (96 to 97) | F: 0.6 (−4.9 to 5.9) | F: 3.5 (3 to 3.9) | F: 1984 (84 to 84) | 3.0 (2.8 to 3.2) | F: 2003 (03 to 03) | ||||
| Germany | M: 1995 (94 to 95) | M: 23.7 (11.5 to 34.2) | NA | M: 7.2 (6.6 to 7.8) | F: 1986 (86 to 87) | F: 0.4 (0.2 to 0.5) | M: 1996 (96 to 97) | 5.8 (5.4 to 6.2) | M: no change |
| F: 1995 (95 to 95) | F: 14.3 (7.7 to 20.5) | F: 6.0 (5.3 to 6.7) | F: 1995 (95 to 96) | 4.7 (4.3 to 5.0) | F: no change | ||||
| Spain | M: 1996 (96 to 96) | M: 24.8 (14.3 to 34.1) | NA | M: 3.7 (3.2 to 4.2) | F: 1993 (93 to 94) | F: 2.1 (1.9 to 2.4) | M: 1984 (83 to 85) | 4.5 (4.2 to 4.7) | M: no change |
| F: 1996 (96 to 96) | F: 22.8 (13.6 to 30.9) | F: 2.5 (2.1 to 3.0) | F: 1984 (84 to 84) | 4.6 (4.4 to 4.8) | F: 2003 (03 to 03) | ||||
| France | M: 1995 (95 to 95) | M: 30.0 (23.0 to 36.4) | NA | M: 3.8 (3.3 to 4.3) | F: 1995 (94 to 97) | F: 1.4 (1.1 to 1.7) | M: 1986 (86 to 86) | 4.9 (4.6 to 5.1) | M: no change |
| F: 1995 (95 to 95) | F: 26 (20.2 to 31.4) | F: 2.9 (2.3 to 3.5) | F: 1981 (81 to 81) | 4.8 (4.6 to 5.0) | F: no change | ||||
| Sweden | M: 1996 (95 to 96) | M: 19.6 (13.3 to 25.5) | NA | M: 4.5 (3.4 to 5.5) | F: 1972 (72 to 72) | F: 0.8 (0.8 to 0.9) | M: 1974 (74 to 75) | 1.7 (1.6 to 1.9) | M: 2000 (99 to 00) |
| F: 1996 (96 to 96) | F: 15.5 (6.8 to 23.3) | F: 3.8 (2.4 to 5.2) | F: 1976 (75 to 76) | 1.9 (1.7 to 2.0) | F: 2002 (02 to 03) | ||||
| The Netherlands | M: 1995 (94 to 95) | M: 22.2 (16.7 to 27.4) | NA | M: 5.0 (4.2 to 5.9) | F: 1991 (90 to 93) | F: 1.5 (1.2 to 1.7) | M: 1991 (90 to 93) | 2.5 (2.2 to 2.9) | M: 2002 (02 to 03) |
| F: 1995 (95 to 95) | F: 14.2 (10.1 to 18) | F: 4.1 (3.0 to 5.1) | F: 1992 (91 to 92) | 1.9 (1.4 to 2.4) | F: 2002 (02 to 03) | ||||
| Estonia | M: no decline | M: no decline | No data | No data | F: 2000 (99 to 02) | F: 1.8 (−0.8 to 4.3) | M: 1994 (93 to 95) | 5.0 (4.4 to 5.7) | M: 2003 (03 to 03) |
| F: no decline | F: no decline | F: 1993 (93 to 94) | 6.4 (4.9 to 5.9) | F: 2003 (03 to 03) |
The % mortality decline per year since start of mortality decline has been obtained by spline regression models. We restricted these models to have only one turning point in the year where mortality starts to decline. For the period between this year and 2005, the slope and its CI have been estimated.
F, female, M, male; NA, not applicable (no start of mortality decline within the study period).